Latest Research Report on Real World Evidence Solutions Market Growth, Industry Revenue Analysis
The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs).
The Real World Evidence Solutions market is valued at 612.0 million in 2017 and projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%.
+ Market Dynamics
+ Drivers
+ Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases
+ Shift From Volume- to Value-Based Care
+ Delays in Drug Development and the Subsequent Increase in Development Costs
Download PDF Brochure @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991
By component, the data sets segment accounted for the largest share of the real world evidence market in 2017.
On the basis of component, the data sets segment accounted for the largest share of the global real world evidence market. The large share can be attributed to factors such as easy availability of massive amounts of data, increasing dependence of outcome-based studies on real-world data, and rising demand for information by payers and providers regarding drug safety.
By therapeutic area, the oncology segment held the largest market share of the real world evidence market in 2017.
Based on therapeutic area, the oncology segment accounted for the largest share of the real-world evidence market in 2017. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.
By end user, the pharmaceutical & medical device companies segment held the largest market share of the real world evidence market in 2017.
Based on end user, the pharmaceutical & medical device companies segment accounted for the largest share of the real world evidence market. The large share of this segment can be attributed to the increasing importance of RWE studies in drug approvals, the need to prevent costly drug recalls, and the increasing need to assess drug performance in real-world settings.
North America dominated the market in 2017.
North America accounted for the largest share of the real world evidence market in 2017, followed by Europe and Asia Pacific. Presence of a favorable regulatory environment, high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real world evidence market.
View complete press release:-
https://www.marketsandmarkets.com/PressReleases/real-world-evidence-solution.asp
